Krystal Biotech Announces Early Evidence of ... - Markets Insider
PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today initial clinical results from its...
Krystal Biotech Announces Early Evidence of Monotherapy …
Dec 18, 2024 · Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial. Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs
News Releases | Investor Relations | Krystal Biotech, Inc.
Dec 9, 2024 · PITTSBURGH , Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third quarter 2024 financial results on Monday, November 4, 2024, prior to the open of U.S. markets.
Krystal Biotech Announces Early Evidence of Monotherapy …
PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today initial clinical results from its...
Krystal Biotech Reports Preliminary Clinical Results for ... - Nasdaq
Dec 18, 2024 · Krystal Biotech, Inc. announced preliminary clinical data from its KYANITE-1 study, which investigated inhaled KB707 as a treatment for advanced non-small cell lung cancer (NSCLC) patients after ...
Krystal Biotech Announces Initial Clinical Update for Rare …
PITTSBURGH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today clinical data updates for both KB408...
Krystal Biotech Receives FDA Approval for the First-Ever …
VYJUVEK is the first-ever redosable gene therapy and the first and only medicine approved by the FDA for the treatment of DEB, both recessive and dominant, that can be administered by a healthcare professional in either a healthcare professional setting or in the home.
Promising Clinical Data and Platform Potential Drive Buy Rating for ...
Dec 19, 2024 · The early results from the phase 1/2 KYANITE-1 trial for KB707, which utilizes Krystal’s HSV-1 vector, show comparable efficacy to existing treatments for non-small cell lung cancer (NSCLC).
Wilmington Savings Fund Society FSB Acquires Shares of 218 Krystal ...
4 days ago · Shares of NASDAQ:KRYS opened at $164.83 on Monday. The company has a market capitalization of $4.74 billion, a PE ratio of 93.12 and a beta of 0.80. Krystal Biotech, Inc. has a 12-month low of ...
Krystal Biotech, Inc. (KRYS) Latest Stock News - Seeking Alpha
Get the latest news and real-time alerts from Krystal Biotech, Inc. (KRYS) stock at Seeking Alpha.
- Some results have been removed